CLAIMS

1. **(Previously Presented)** A kit for the combined use for the treatment of cancer patients, which set comprises the following components:

a) an antigen comprising at least one epitope of a cellular surface protein, or an antibody directed against the cellular surface protein, and

b) an antigen comprising at least one epitope of an aberrant protein glycosylation, or an antibody directed against the aberrant protein glycosylation.

2. **(Original)** A kit according to claim 1, characterized in that the components a) and b) are contained in one pharmaceutical preparation each or in a single pharmaceutical preparation suitable for immunotherapy.

3. **(Original)** A kit according to claim 2, characterized in that the pharmaceutical preparation is formulated as a vaccine.

4. **(Original)** A kit according to claim 2, characterized in that the pharmaceutical preparation is formulated as an intravenously tolerable product.

5. **(Previously Presented)** A kit according to claim 1, characterized in that the antigen of component a) represents an epitope of a cellular adhesion protein, in particular of a protein selected from the group of EpCAM, NCAM and CEA.

6. **(Previously Presented)** A kit according to claim 1, characterized in that the antigen of component a) is an epitope of a surface receptor, in particular a receptor molecule selected from the group of the EGF receptor family, CD55 receptor, transferrin receptor and P-glycoprotein.

7. **(Previously Presented)** A kit according to claim 1, characterized in that the antigen of component b) represents an epitope of a carbohydrate selected from the group of Lewis antigens, in particular Lewis y and/or Lewis b, sialyl-Tn and Globe H.

8. **(Previously Presented)** A kit according to claim 1, characterized in that the antigen of component a) represents an epitope of the EpCAM molecule or of the Her-2/neu receptor, and the antigen of component b) represents an epitope of the Lewis Y molecule_

9. **(Previously Presented)** A method for the immunologic determination of tumor cells of a solid tumor or disseminated tumor cells of a cancer disease which comprises

a) exposing a sample from a cancer patient to:

(i) an antigen comprising at least one epitope of a cellular surface protein, or an antibody directed against the cellular surface protein, and

(ii) an antigen comprising at least one epitope of an aberrant protein glycosylation, or an antibody directed against the aberrant protein glycosylation; and

b) determining the immunological response.

10. **(Previously Presented)** The method according to claim 9, wherein the determination is carried out within the scope of the treatment of cancer patients.

11. **(Previously Presented)** The method according to claim 9, wherein said sample comprise tumor cells from samples of peripheral blood or bone marrow.

12. **(Previously Presented)** The method according to claim 9 or 10, wherein an antibody titer against the antigens of the components is determined.

13. **(Previously Presented)** The method according to claim 12, wherein the determination is carried out for monitoring a treatment of a cancer patient.

14. **(Previously Presented)** A method for immunologic selection of a tumor-specific target antigen or of antibodies directed against the target antigen by exposing a sample from a cancer patient to

(a) an antigen comprising at least one epitope of a cellular surface protein, or an antibody directed against the cellular surface protein, and

(b) an antigen comprising at least one epitope of an aberrant protein glycosylation, or an antibody directed against the aberrant protein glycosylation; wherein

the antigen is a neoepitope which is formed by the glycosylatien of an antigen of component a) with an antigen of component b).

15. **(Previously Presented)** An antigen composition which comprises a neoepitope or its mimic, prepared by the method according to claim 14.

16. **(Previously Presented)** A composition according to claim 15 wherein the antigen is a naturally occurring antigen or a fragment thereof.

17. **(Previously Presented)** A method according to claim 14, wherein an antibody directed against the neoepitope is selected and prepared by using a kit according to claim 1.

18. **(Previously Presented)** An antibody composition with specificity for a neo-epitope, prepared by the method according to claim 17.

19. **(Original)** A diagnostic agent based on a kit according to claim 1, characterized in that it contains a reagent for determining an immune reaction with components a) and b), or with antibodies against these.

20. **(Previously Presented)** An agent according to claim 19, wherein the reagent is labelled with a fluorescent agent, a chromogen, a radiolabel or an enzyme.

21. **(Previously Presented)** An agent according to claim 20, wherein the reagent is immobilized on a carrier.

22. **(Previously Presented)** An agent according to claim 21, wherein the carrier is a matrix for immunoaffinity chromatography.

23. **(New)** A kit according to claim 1, wherein said antigen of paragraph (a) is EpCAM, and said antigen of paragraph (b) is Lewis Y.